Article Versions Notes

Ma X, Ding Y, Qian J, Wan M, Li N, Mao C, Xiao C, Jiang H, Zheng Y, Wu L, et al. Nomogram Based on Monocyte-to-Lymphocyte Ratio to Predict Survival of Unresectable Esophageal Squamous Cell Carcinoma Who Receive First-Line PD-1/PD-L1 Inhibitors Combined with Chemotherapy. Current Oncology. 2022; 29(11):8937-8954. https://doi.org/10.3390/curroncol29110702

Ma, Xiaolu, Yongfeng Ding, Jiong Qian, Mingyu Wan, Ning Li, Chenyu Mao, Cheng Xiao, Haiping Jiang, Yulong Zheng, Luntao Wu, and et al. 2022. "Nomogram Based on Monocyte-to-Lymphocyte Ratio to Predict Survival of Unresectable Esophageal Squamous Cell Carcinoma Who Receive First-Line PD-1/PD-L1 Inhibitors Combined with Chemotherapy" Current Oncology 29, no. 11: 8937-8954. https://doi.org/10.3390/curroncol29110702

Ma, X., Ding, Y., Qian, J., Wan, M., Li, N., Mao, C., Xiao, C., Jiang, H., Zheng, Y., Wu, L., Chen, X., & Xu, N. (2022). Nomogram Based on Monocyte-to-Lymphocyte Ratio to Predict Survival of Unresectable Esophageal Squamous Cell Carcinoma Who Receive First-Line PD-1/PD-L1 Inhibitors Combined with Chemotherapy. Current Oncology, 29(11), 8937-8954. https://doi.org/10.3390/curroncol29110702